Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com .

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

    CONTACT:  Paul Donovan

              508-650-8541 (office)

              508-667-5165 (mobile)

              Media Relations

              Boston Scientific Corporation


              Dan Brennan

              508-650-8538 (office)

              617-459-2703 (mobile)

              Investor Relations

              Boston Scientific Corporation

(1) The TAXUS Liberte stent is currently pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

(2) Defined as B2 or C lesions (ACC/AHA lesion type)

Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541, Mobile,+1-508-667-5165, or Dan Brennan, Investor Relations, +1-508-650-8538,Mobile, +1-617-459-2703, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Busi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , BURLINGTON, Mass., Oct. 16 Palomar Medical ... researcher and developer of light-based systems for cosmetic ... with Johnson & Johnson Consumer Companies Inc ("JJCC"), ... test and commercialize home-use, light-based devices for (i) ...
... 16 Reportlinker.com announces that a new market ... Reportlinker Adds Pharma 101: An Overview ... , http://www.reportlinker.com/p0155107/Reportlinker-Adds-Pharma-101-An-Overview-of-the-Life-Sciences-Industry-(Analyst-Insight).html , Introduction , ... Without having the proper background, it can be ...
Cached Medicine Technology:Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 2Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 3Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 4Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 5Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight) 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... several commonly-prescribed dementia drugs may be putting elderly Canadians ... , Cholinesterase inhibitors (Aricept, Exelon and Reminyl) are often ... because they increase the level of a chemical in ... drugs are known to provoke slower heart rates and ...
... Public Welfare Estelle B. Richman today responded to critics ... save taxpayers $146 million annually while preserving consumer benefits ... from the Smart Pharmacy initiative are real, not speculative," ... is facing a budget shortfall now and the savings ...
... pain condition common in people with migraines also ... headache, according to a study conducted by researchers ... for Neuroscience. , Approximately half of a group ... a condition that causes patients to have pain ...
... 27 UNICEF has appealed for an additional ... fighting in northwest Pakistan. Over half of the displaced are ... of supplies and funding. , , Humanitarian ... the number of people fleeing fighting that has taken place ...
... of Tennessee and Daiichi Sankyo ATLANTA, ... headquartered in Atlanta, has recently been awarded business ... BlueShield of Tennessee and Daiichi Sankyo, Inc.Studiocom,s healthcare ... these new clients meeting the challenges of the ...
... DIEGO, May 27 ResMed Inc. (NYSE: RMD ... upcoming conferences. David Pendarvis, SVP Organization Development and General Counsel ... the Four Seasons in Chicago on June 10, 2009 at ... CEO will present at the Jefferies Third Annual Healthcare Conference ...
Cached Medicine News:Health News:Dementia drugs may put some patients at risk, Queen's study shows 2Health News:Secretary of Public Welfare Corrects the Record on 'Smart Pharmacy' Initiative 2Health News:UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 3
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... protection' -- providing complete protection from initial ... with side branches. , ,Proxis is ... not require the attachment or exchange of ... ,Proxis is compatible with all standard ...
... electrophysiology system on the market today, the ... patented "C inside a C" design offering ... ultimate in patient access and flexibility. Usable ... minimizes equipment footprint and can be parked ...
Medicine Products: